Abstract: Disclosed herein are compositions including diphenhydramine, or a pharmaceutically acceptable salt thereof, and a liquid vehicle. The compositions may be administered intranasally to patients in need of diphenhydramine. The compositions provide increase plasma and brain concentrations relative to orally administered compositions, but without the limitations associated with intravenously administered compositions.

Abstract: Disclosed herein are compositions including diphenhydramine, or a pharmaceutically acceptable salt thereof, and a liquid vehicle. The compositions may be administered intranasally to patients in need of diphenhydramine.

Abstract: Disclosed herein are compositions including diphenhydramine, or a pharmaceutically acceptable salt thereof, and a liquid vehicle. The compositions may be administered intranasally to patients in need of diphenhydramine. The compositions provide increase plasma and brain concentrations relative to orally administered compositions, but without the limitations associated with intravenously administered compositions.

Abstract: Methods and compositions for treating specific patient groups for Central Nervous System disorders, including but not limited to Tourette Syndrome, are provided. The methods of the present invention comprise the utilization of pharmaceutical compositions comprising quinolinones (and derivatives thereof) in patients with symptoms of a Central Nervous System Disorder who are otherwise free of cardiac disease and/or who have not been given organic nitrates.

Abstract: The present invention is directed to compositions and methods for treating cardiovascular disease. In a preferred embodiment, the present invention contemplates using the enantiomers of flosequinan (and formulations comprising flosequinan) in subjects not concurrently treated with nitrites or nitrates.

Abstract: Methods and compositions for treating specific patient groups for Central Nervous System disorders, including but not limited to Tourette Syndrome, are provided. The methods of the present invention comprise the utilization of pharmaceutical compositions comprising quinolinones (and derivatives thereof) in patients with symptoms of a Central Nervous System Disorder who are otherwise free of cardiac disease and/or who have not been given organic nitrates.

Abstract: The present invention is directed to methods for treating cardiovascular disease comprising administering the enantiomers of flosequinan in subjects not concurrently treated with nitrites or nitrates.

Abstract: Methods for treating specific patient groups for sexual dysfunction are provided. The methods of the present invention comprise the utilization of enantiomers of flosequinan, and pharmaceutical compositions comprising flosequinan enantiomers, in patients who are free of cardiac disease, who have not been treated with a drug that causes hypotensive effects, and/or who have not been given organic nitrites or nitrates. Flosequinan enantiomers, and pharmaceutical compositions comprising flosequinan enantiomers are administered to patients intranasally, orally, topically, and/or through respiratory inhalation.

Abstract: Methods and compositions for treating specific patient groups for Central Nervous System disorders, including but not limited to Tourette Syndrome, are provided. The methods of the present invention comprise the utilization of pharmaceutical compositions comprising quinolinones (and derivatives thereof) in patients with symptoms of a Central Nervous System Disorder who are otherwise free of cardiac disease and/or who have not been given organic nitrates.

Abstract: The present invention is directed to compositions and methods for treating cardiovascular disease. In a preferred embodiment, the present invention contemplates using the enantiomers of flosequinan (and formulations comprising flosequinan) in subjects not concurrently treated with nitrites or nitrates.

Abstract: Methods for treating specific patient groups for gastroparesis are provided. The methods of the present invention comprise the utilization of pharmaceutical compositions comprising quinolinones (and derivatives) in patients with symptoms of gastroparesis who are otherwise free of cardiac disease and/or who have not been given organic nitrates.

Abstract: Methods and compositions for treating specific patient groups for Central Nervous System disorders, including but not limited to Tourette Syndrome, are provided. The methods of the present invention comprise the utilization of pharmaceutical compositions comprising quinolinones (and derivatives thereof) in patients with symptoms of a Central Nervous System Disorder who are otherwise free of cardiac disease and/or who have not been given organic nitrates.

Abstract: Methods for treating specific patient groups for gastroparesis are provided. The methods of the present invention comprise the utilization of pharmaceutical compositions comprising quinolinones (and derivatives) in patients with symptoms of gastroparesis who are otherwise free of cardiac disease and/or who have not been given organic nitrates.

Abstract: A composition, that imparts or enhances hydrophilic properties to a surface on which the composition is applied, comprises i) an associative polymeric thickening agent; and ii) a compound represented by the chemical structure: wherein Z=H, CH3, or C2H5; Y=H, CH3, or C2H5; M=1 to 30; N=0 to 30; R1=H, CH3, C2H5, a branched or unbranched C8-22 alkane or alkene substituent, or nothing; R2=H, CH3, C2H5, a branched or unbranched C8-22 alkane or alkene substituent, O, or nothing; X=N, O, S, P, Si, PO3, or SO3; and Y=R2 when N=0.

Abstract: Disclosed herein are fabric cleaning solutions such as clothing pre-spotters. The solutions have a mildly acidic pH and contain an amphoteric surfactant. They can be used many hours, or even a few days, before laundering in standard base detergent conditions. The solutions provide the equivalent of a "bucketless soak.

Abstract: Disclosed herein are surfactant complexes and methods for using them. The complexes contain nonionic surfactants in low concentrations. The surfactants are complexes with associative polymeric thickeners. These complexes can be formulated for use as laundry pre-spotters, hard surface cleaners, and insecticides. They can also be used in other applications.

Abstract: Disclosed herein are methods for use of a towelette to clean stains from clothing and upholstery. The towelette is impregnated with a cleaning solution that is primarily water, but also contains a volatile cleaning agent and a surfactant. The pH and surfactant concentrations of the cleaning solution are regulated. The wipe reduces the incidence of readily visible rings around treated stains.

Abstract: The present invention provides laundry pre-spotter compositions with superior cleaning efficacy using associative polymeric thickeners to synergistically boost cleaning. Cleaning efficacy equivalent to compositions comprising having twice the amount of a nonionic surfactant by weight and a viscosity from about 300 cps to about 100,000 cps at 25.degree. C. and 60 RPM is obtained by employing a composition comprising from about 7.0 or 9.0% to about 13.0% by weight of at least one nonionic surfactant having an average HLB of from about 8 to about 13 and about 0.25% to about 2.0% by weight of at least one associative polymeric thickener.

Abstract: The present invention provides laundry pre-spotter compositions with superior cleaning efficacy using associative polymeric thickeners to synergistically boost cleaning. Cleaning efficacy equivalent to compositions comprising having twice the amount of a nonionic surfactant by weight and a viscosity to about 100,000 cps at 25.degree. C. is obtained by employing a composition comprising from about 12.5% to about 13.0% by weight of at least one nonionic surfactant having an average HLB of from about 8 to about 13 and about 0.4% to about 2.0% by weight of at least one associative polymeric thickener.

Abstract: A multiplexed sigma delta analog-to-digital (A/D) converter for low frequency applications has a single oversampling modulator together with a relatively high cutoff lowpass filter together with individual line frequency (50 or 60 Hz) rejection filters for each output channel.